George Zachary

George Zachary established CRV’s Bioengineering practice in August of 2016. In addition to investing in Glympse, he has led the firm’s investments in PillPack, a full-service, technology-based pharmacy that was acquired by Amazon in 2018; Wild Type, a company that creates clean and sustainable fish and meat through cellular agriculture technologies; System1 Biosciences, a neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases; Freenome, a company applying deep learning to cell-free DNA for early cancer detection; HealthIQ, a technology-based insurance company that uses artificial intelligence to provide the best rates for health-conscious individuals; Color Genomics; and Recursion Pharma. He was also the first and lead institutional investor in a number of the world’s most iconic companies including Twitter (TWTR), Yammer ($1B acquisition by MSFT), Shutterfly (SFLY), and Udacity.

George brings over 20 years of computing and consumer technology experience to his role as an investor, having previously been a general partner at Mohr Davidow Ventures (MDV), and leading the Nintendo 64 development business at Silicon Graphics. He earned a joint B.S. in Computer Science and Management Science from MIT and MIT Sloan School of Business, is on the board of StartX, and is also an advisor to the XPRIZE Foundation.